Our Mission
Immunyx is pioneering new approaches to immune modulation using targeted nanoparticles to change the function of neutrophils. Our team of world experts in neutrophil biology and nanoparticle development are using cutting edge tools to bring new therapies to patients across a broad spectrum of diseases. The company was founded based on technology from the Hebrew University with the backing of VLX Ventures.
Management
Seth Salpeter, Ph.D
Co-Founder & CEO
Dr. Salpeter has deep experience in developing and bringing new biotechnologies to market. He previously served as Co-Founder and CTO at Curesponse, a precision cancer medicine company. Prior to that he was Chief Scientist and VP Business Development at Sight Diagnostics. Dr. Salpeter holds a Ph.D in Biochemistry from the Hebrew University and performed post-doctoral studies at the Institute for Drug Research, the Hebrew University School of Pharmacy
Zvika Granot, Ph.D
Co-Founder & CSO
Dr. Granot is a Professor at the Hebrew University School of Medicine. After receiving his Ph.D at the Hebrew University, he performed post-doctoral work at Memorial Sloan Kettering where he focused on the role of neutrophil biology in cancer. Since launching his laboratory he has continued to research the neutrophil’s role in disease, recently discovering the high and low density paradigm of neutrophil regulation.
Zvi Fridlender, M.D, Ms.C
Co-Founder & CMO
Dr. Fridlender is a Professor at the Hebrew University Medical School Hadassah Hospital where he is director of the Lung COPD unit and head of the Lung Cancer laboratory. Dr. Fridlender performed post-doctoral work at the University of Pennsylvania where he discovered the N1 & N2 neutrophil phenotypes in cancer. In his own laboratory, he continues to focus on the role of neutrophils in cancer and their interaction with the microenvironment.
Scientific Advisory Board
Dr. Daryl Drummond, Ph.D
Chief Scientific Officer at Akagera Medicines, Inc and Interim Head of R&D – Tidal Therapeutics
International expert in targeted therapies.
Prof. Chezy Barenholz
Inventor of Doxil, international expert in liposomes
Ronit Satchi-Fainaro, Ph.D
Expert in nano-particle delivery and preclinical systems.